Nicholls Stephen J, Bubb Kristen J
Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Biomedical Discovery Institute, Monash University, Melbourne, Australia.
Curr Cardiol Rep. 2021 Jul 1;23(8):97. doi: 10.1007/s11886-021-01528-w.
Despite widespread targeting of cardiovascular risk factors, many patients continue to experience clinical events. This residual risk has stimulated efforts to develop novel therapeutic approaches to target additional factors underscoring cardiovascular disease. This review aimed to summarize existing evidence supporting targeting of Lp(a) as a novel cardioprotective strategy.
Increasing evidence has implicated lipoprotein (a) [Lp(a)] in the pathogenesis of both atherosclerotic and calcific aortic valve disease. Therapeutic advances have produced novel agents that selectively lower Lp(a) levels, which have now progressed to evaluate their impact on cardiovascular events in large clinical outcome trials. Evidence continues to accumulate suggesting that targeting Lp(a) may be effective in reducing cardiovascular risk. With advances in Lp(a) targeted therapeutics, clinical trials now have the opportunity to determine whether this strategy will be effective for high-risk patients.
尽管广泛针对心血管危险因素进行干预，但仍有许多患者继续发生临床事件。这种残余风险促使人们努力开发新的治疗方法，以针对其他导致心血管疾病的因素。本综述旨在总结支持将脂蛋白（a）[Lp（a）]作为一种新型心脏保护策略进行靶向治疗的现有证据。
越来越多的证据表明脂蛋白（a）[Lp（a）]在动脉粥样硬化和钙化性主动脉瓣疾病的发病机制中起作用。治疗方面的进展已产生了能选择性降低Lp（a）水平的新型药物，目前这些药物已进入大型临床结局试验，以评估它们对心血管事件的影响。越来越多证据表明针对Lp（a）可能有效降低心血管风险。随着Lp（a）靶向治疗的进展，临床试验现在有机会确定该策略对高危患者是否有效。
